HCW Biologics Inc. (NASDAQ:HCWB) Sees Large Growth in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 11,700 shares, a growth of 69.6% from the July 31st total of 6,900 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 16,800 shares, the short-interest ratio is currently 0.7 days.

HCW Biologics Stock Up 4.3 %

HCW Biologics stock opened at $0.49 on Thursday. The company has a 50 day moving average of $0.61 and a 200-day moving average of $1.10. The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.95. HCW Biologics has a twelve month low of $0.40 and a twelve month high of $2.18. The stock has a market capitalization of $18.53 million, a PE ratio of -0.64 and a beta of 0.81.

Hedge Funds Weigh In On HCW Biologics

A hedge fund recently bought a new stake in HCW Biologics stock. Pullen Investment Management LLC acquired a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 85,116 shares of the company’s stock, valued at approximately $149,000. Pullen Investment Management LLC owned 0.23% of HCW Biologics at the end of the most recent reporting period. 2.96% of the stock is owned by institutional investors.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.